ReviewInternational journal of molecular sciences2023
Etiopathogenesis and Emerging Methods for Treatment of Vitiligo.
Review in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 36 citations in OpenAlex.
- From Mechanisms to Clinical Practice: Advances in Vitiligo Treatment Across Western Medicine and Traditional Chinese Medicine.Clinical, cosmetic and investigational dermatology · 2026Review
- Understanding vitiligo-related concerns through online discourse: an AI-assisted cross-platform study of Chinese and global communities.Frontiers in public health · 2026Article
- Dermatoscopic markers of disease activity in vitiligo.JAAD international · 2025Article
- Linking IFN-γ-Mediated Pathogenesis to ROCK-Targeted Therapy in a Scalable iPSCs-Based Vitiligo Model.International journal of molecular sciences · 2025Article
- Canadian Consensus Guidelines for the Management of Vitiligo.Dermatology and therapy · 2025Article
- Short-term efficacy and safety of upadacitinib combined with 308 excimer light versus upadacitinib alone and 308 excimer light alone in patients with progressing facial vitiligo.Archives of dermatological research · 2025Article
- Bioinformatic analysis of ferroptosis related biomarkers and potential therapeutic targets in vitiligo.Scientific reports · 2025Article
- Evidence from a Comprehensive Bioinformatics Analysis Point to Possible Therapeutic Targets for Vitiligo.Clinical, cosmetic and investigational dermatology · 2025Article
- Identification of Oxidative Stress-Related Shared Biomarkers in Vitiligo and Periodontitis: A Bioinformatics and Machine Learning Study.Clinical, cosmetic and investigational dermatology · 2025Article
- Screening for Biomarkers Related to Pigmentation and Formation in Vitiligo.Combinatorial chemistry & high throughput screening · 2025Article
- Treatment of vitiligo with topical ruxolitinib: a narrative review.Drugs in context · 2025Review
- Exploring the influence of gut microbiota metabolites on vitiligo through the gut-skin axis.Frontiers in microbiology · 2025Review
- Role of Cytokines and Chemokines in Vitiligo and Their Therapeutic Implications.Journal of clinical medicine · 2024Review
- Afamelanotide in protoporphyria and other skin diseases: a review.Postepy dermatologii i alergologii · 2024Review
- Transcutaneous Auricular Vagus Nerve Stimulation Alleviates Monobenzone-Induced Vitiligo in Mice.International journal of molecular sciences · 2024Article
- Human Mesenchymal Stem Cell-Derived Exosomes Promote the Proliferation and Melanogenesis of Primary Melanocytes by Attenuating the HClinical, cosmetic and investigational dermatology · 2024Article
- Vitiligo: Clinical and Laboratory Characteristics in 573 Saudi Patients.Clinical, cosmetic and investigational dermatology · 2024Article
- Updates on Potential Therapeutic Approaches for Vitiligo: Janus Kinase Inhibitors and Biologics.Journal of clinical medicine · 2023Review
- Antioxidant mechanisms of mesenchymal stem cells and their therapeutic potential in vitiligo.Frontiers in cell and developmental biology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Vitiligo is an acquired chronic depigmenting disorder of skin. It is mostly asymptomatic and characterized by amelanotic macules and patches that affects 0.5% to 2% of the world's population. The etiology of vitiligo has not been clearly elucidated and multiple theories have been proposed regarding the causes of the disorder. Among the most prevalent theories, the genetic predisposition, oxidative stress theory, promotion of cellular stress and pathologic influence of lymphocytes T have been highlighted. As a result of increases in in-depth knowledge concerning the pathogenetic processes in vitiligo, we review the most recent information concerning its etiopathogenesis and treatment methods including topical and oral Janus kinase inhibitors, prostaglandins and their analogues, namely afamelanotide, Wnt/β-catenin-signaling agonists and cell-based therapies. Topical ruxolitinib has been registered for vitiligo treatment, whereas other agents as oral ritlecitinib, afamelanotide and latanoprost have been studied in ongoing clinical trials. New highly effective therapeutic strategies may be developed thanks to molecular and genetic studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.